Shire’s NPS Purchase Highlights Its Orphan Drug Strategy Post-AbbVie Bid
Executive Summary
The Dublin-based drugmaker’s buy of rare disease specialist NPS Pharma signals it is back on the offensive after AbbVie’s aborted bid, but observers say the deal’s sound logic may make Shire a takeover target again.